c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

European Journal of Haematology
Alessandra Di BaccoPhilippe Moreau

Abstract

In the TOURMALINE-MM1 phase 3 trial in relapsed/refractory multiple myeloma, ixazomib-lenalidomide-dexamethasone (IRd) showed different magnitudes of progression-free survival (PFS) benefit vs placebo-Rd according to number and type of prior therapies, with greater benefit seen in patients with >1 prior line of therapy or 1 prior line of therapy without stem cell transplantation (SCT). RNA sequencing data were used to investigate the basis of these differences. The PFS benefit of IRd vs placebo-Rd was greater in patients with tumors expressing high c-MYC levels (median not reached vs 11.3 months; hazard ratio [HR] 0.42; 95% CI, 0.26, 0.66; P < .001) compared with in those expressing low c-MYC levels (median 20.6 vs 16.6 months; HR 0.75; 95% CI, 0.42, 1.2). Expression of c-MYC in tumors varied based on the number and type of prior therapy received, with the lowest levels observed in tumors of patients who had received 1 prior line of therapy including SCT. These tumors also had higher expression levels of CD19 and CD81. PFS analyses suggest that lenalidomide and ixazomib target tumors with different levels of c-MYC, CD19, and CD81 expression, thus providing a potential rationale for the differential benefits observed in the TOUR...Continue Reading

References

Dec 22, 1998·Molecular and Cellular Biology·C V Dang
Nov 29, 2001·Nature Immunology·K L Calame
May 7, 2002·Nature Reviews. Cancer·W Michael Kuehl, P Leif Bergsagel
Jun 15, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Pei LinJohn D Shaughnessy
Nov 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shmuel Yaccoby
Feb 7, 2008·European Journal of Immunology·Paolo CascioRoberto Sitia
Jun 19, 2008·Bone Marrow Transplantation·Sk KumarMa Gertz
Mar 28, 2012·Biochemical and Biophysical Research Communications·Jing-li GuChang Su
Apr 14, 2012·Blood·Jonathan J KeatsP Leif Bergsagel
Oct 2, 2012·The Journal of Clinical Investigation·W Michael Kuehl, P Leif Bergsagel
Aug 3, 2013·Cold Spring Harbor Perspectives in Medicine·Chi V Dang
Oct 1, 2013·Bone Marrow Transplantation·C Fernández de LarreaJ Bladé
Oct 12, 2013·British Journal of Haematology·Roman HajekHana Svachova
May 23, 2014·Leukemia & Lymphoma·Isabella C GlitzaMuzaffar H Qazilbash
Aug 8, 2014·BioMed Research International·Sanjay de MelWee-Joo Chng
Dec 10, 2014·Clinical Lymphoma, Myeloma & Leukemia·Annamaria BrioliGareth J Morgan
Sep 10, 2015·The New England Journal of Medicine·Alfred L GarfallEdward A Stadtmauer
Apr 9, 2016·Oncotarget·Michel JourdanBernard Klein
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Nov 3, 2016·Nature Reviews. Clinical Oncology·Salomon ManierIrene M Ghobrial
Feb 23, 2018·Leukemia·K K JovanovićS Manier

❮ Previous
Next ❯

Citations

Oct 26, 2020·Molecular Oncology·Katharina LankesMatthias Wirth

❮ Previous
Next ❯

Methods Mentioned

BETA
RNAseq

Clinical Trials Mentioned

NCT01564537

Related Concepts